Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis

BACKGROUND: The combination of bevacizumab and irinotecan is a new chemotherapy protocol increasingly used for recurrent malignant glioma. Results from phase II trials suggest this drug combination is beneficial to patients, but no conclusive comparisons between this and other treatment protocols ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Tao, Chen, Juxiang, Lu, Yicheng, Wolff, Johannes EA
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891637/
https://www.ncbi.nlm.nih.gov/pubmed/20525214
http://dx.doi.org/10.1186/1471-2407-10-252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891637/
https://www.ncbi.nlm.nih.gov/pubmed/20525214
http://dx.doi.org/10.1186/1471-2407-10-252

Ejemplares similares